ваше письмо отправлено.
Pharmimex core business is to purchase and distribute products including substances, pharmaceutical products, therapeutic cosmetics and side-line products; to manufacture medicines and drugs; to register medicines and drugs.
Orphan diseases. Pharmimex JSC is authorized to import unregistered pharmaceutical products subject to assignment to the patients suffering from orphan diseases to the area of the Russian Federation under the decision issued by the Ministry of Public Health of the Russian Federation.
Pharmimex JSC maintains its business relationships with more than 230 medical product manufacturers and suppliers including 119 companies operating in other 33 countries, in particular: Austria, Burglary, Hungary, Holland, Germany, Greece, Denmark, India, Italy, Latvia, Macedonia, the Netherlands, Slovenia, the USA, France, Finland, Check Republic, Switzerland, Yugoslavia, and Japan etc.
The Company is engaged in procurement of pharmaceutical products under long-term contracts concluded with manufacturers, thereby providing a wide range of products, ensuring on-time delivery of medicines, and keeping out of any supplies of faulty products.
Long-term relationships with suppliers, joint scheduling, exchange of information, and comfortable terms of payments are the very factors that help Pharmimex to effectively run its stock of goods while storing reserve stocks as those that are considered critical for the pharmaceutical products to be in short supply.
Pharmimex trades with a number of foreign companies under special pharmaceutical product procurement agreements (Octapharma, Biotest Phama, Remedica, Orion Corporation, Biogen Idec France, Novartis, Shire, Alexion etc.).